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Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive therapy that has 
been implicated in treatment of serious neurological disorders. However, the neurobio-
logical mechanisms underlying the effects of rTMS remain unclear. Therefore, this study 
examined the differential effects of repetitive magnetic stimulation (rMS) in an in  vitro 
neuronal model of ischemia/reperfusion (I/R) injury, depending on low and high fre-
quency. Neuro-2a cells were differentiated with retinoic acid and established for in vitro 
neuronal model of I/R injury under a subsequent 3 h of oxygen and glucose deprivation/
reoxygenation (OGD/R) condition. After the I/R injury, the differentiated neuronal cells 
were stimulated with rMS on day 1 and randomly divided into three groups: OGD/
R+sham, OGD/R+low-frequency, and OGD/R+high-frequency groups. High-frequency 
rMS increases cell proliferation through activation of extracellular signal-regulated 
kinases and AKT-signaling pathway and inhibits apoptosis in OGD/R-injured cells. 
Furthermore, high-frequency rMS increases Ca2+–calmodulin-dependent protein kinase 
II (CaMKII)-cAMP-response element binding protein (CREB) signaling pathway, further 
leading to alternation of brain-derived neurotrophic factor expression and synaptic plas-
ticity in OGD/R injured cells. These results verified the neurobiological mechanisms of 
frequency-dependent rMS in I/R injury-treated neuronal cells. These mechanisms will 
help develop more powerful and credible rTMS stimulation treatment protocols.
Keywords: repetitive magnetic stimulation, in vitro neuronal model of ischemia/reperfusion injury, extracellular 
signal-regulated kinases and aKT signaling pathway, apoptosis, ca2+–calmodulin-dependent protein kinase ii-
caMP-response element binding protein signaling pathway, brain-derived neurotrophic factor, synaptic plasticity, 
high frequency
inTrODUcTiOn
Magnetic stimulation produces current flow in the nerve tissue and causes neuronal depolarization 
(1, 2). Transcranial magnetic stimulation (TMS) generates current flow in the brain without direct 
contact with the scalp and can be used to assess and control the excitability of certain regions of the 
brain (1, 3). When induced at a regular frequency, these TMS pulses are called repetitive transcranial 
magnetic stimulation (rTMS) (4).
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rTMS is a non-invasive and less painful method to induce 
brain stimulation with no significant side effects (1, 5). rTMS is 
used as a treatment for a wide range of neurologic diseases, such 
as stroke and movement disorders, psychiatric diseases, and pain 
syndromes (6).
Several studies have demonstrated that the excitability of the 
cortex can be differentially modulated by intensity, frequency, 
and the overall pattern of the rTMS (3). Frequency is an impor-
tant factor that can control cortical excitability. High-frequency 
(>3 Hz) stimulation usually has an effect of facilitation while low-
frequency (≤1 Hz) stimulation has a lowering effect of synaptic 
efficiency (7–11).
In stroke patients, the motor dysfunction of paretic limb is 
accompanied by decreased ipsilesional cortical excitability and 
increased interhemispheric inhibition (IHI) due to the increased 
contralesional cortical excitability (12). Therefore, rTMS in stroke 
patients can improve the function of paretic limb by increasing 
ipsilesional cortical excitability by applying high frequency rTMS to 
ipsilesional hemisphere (13–15). There are also several studies that 
improve the excitability of the ipsilesional cortex via the reduction 
of the IHI by applying low frequency rTMS to the contralesional 
hemisphere to improve the function of the paretic limb (16–20).
Furthermore, rTMS treatment is known to affect the regula-
tion of brain plasticity in ischemic stroke patients (21). There 
are several studies to support neurotrophic factor-mediated 
brain plasticity as to a mechanism of stroke rehabilitation, and 
it is known that the expression of brain-derived growth factor 
(BDNF), which plays an important role in brain plasticity, 
changes in association with synaptic activity (22). In addition, 
several in vitro and in vivo studies have shown that rTMS affects 
the expression of various neurotrophic/growth factors, including 
BDNF, and neuroblastoma cell proliferation, which has been veri-
fied by the various frequencies of rTMS (23–25).
In ischemic stroke, brain injury is caused by ischemia as well 
as cell damage induced by reperfusion injury (26). Oxygen and 
glucose deprivation/reoxygenation (OGD/R) is well established 
in an in vitro model for the study of ischemic/reperfusion (I/R) 
injury of neurons (27, 28). A previous research confirms that the 
injury induced by OGD/R can mimic the I/R injury in an in vivo 
model of ischemic stroke (29).
Although considerable research has been done on the thera-
peutic use of rTMS for brain ischemic injury, the precise mecha-
nism is still elusive. Therefore, to understand the therapeutic 
effect and mechanism of rTMS, it is necessary to combine the 
mechanism based on brain plasticity. In this study, we aimed to 
investigate the differential effects of repetitive magnetic stimula-
tion (rMS) depending on frequency in an in vitro neuronal model 
of I/R injury using OGD/R.
MaTerials anD MeThODs
cell cultures
Neuro-2a (N2a) cells were purchased from American Type 
Culture Collection biotechnology (ATCC, Manassas, VA, USA). 
N2a cells were derived from mouse neuroblastoma, which exhib-
its properties of neuronal stem cells and could differentiate into 
neuronal cells when treated with retinoic acid (RA). N2a cells were 
maintained in growth medium, which were Dulbecco’s Modified 
Eagle Medium (DMEM; Hyclone, Logan, UT, USA) contain-
ing 10% fetal bovine serum (FBS; Serum Source International, 
Charlotte, NC, USA) and 1% Penicillin–Streptomycin solution 
(Gibco, Rockville, MD, USA), in a humidified 5% CO2 atmosphere 
at 37°C. When N2a cells reached 70–80% confluency, the medium 
was changed into differentiation medium, which contain 2% FBS 
and 20 µM of RA in DMEM, for 4 days. Differentiated N2a cells 
were maintained in a humidified atmosphere of 5% CO2 at 37°C, 
and the differentiation medium was changed every 2 days.
OgD/r and rMs
The following procedures have been adapted from previous stud-
ies (29–31). Confluent-differentiated N2a cells were washed three 
times with phosphate-buffered saline (PBS) and the differentiation 
medium was replaced with deoxygenated, glucose-free balanced 
salt solution (Gibco), and transferred to a hypoxic chamber (O2 
tension 1%) for 3 h. Following OGD, injured cells were replaced 
with growth medium and stimulated with customized rMS 
(Bicon-1000Pro, Mcube Technology, Seoul, Korea). The magnetic 
coil (70-mm diameter) was placed and positioned 1  cm away 
from the cell culture dish. OGD/R cells were divided into three 
groups, as the OGD/R+sham group (placing the culture dishes 
without magnetic stimulation), the OGD/R+low-frequency 
group (0.5 Hz stimulation, on–off interval of 3 s), and the OGD/
R+high-frequency group (10 Hz stimulation, on–off interval of 
3 s) for 10 min. After the stimulation, cells were incubated in a 
humidified atmosphere of 5% CO2 at 37°C. After 24  h, OGD/
R+rMS cells were harvested using 0.25% trypsin-EDTA (Gibco). 
The experimental schedule is presented in Figure 1. All proce-
dures of the cells were observed under microscope and changed 
morphology was photographed with a digital imaging system 
(Eclipse TS100; Nikon USA, Melville, NY, USA) in Figure 2A.
cell Proliferation
To analyze the proliferation of the cells, the number of OGD/
R+rMS cells was calculated with an advanced detection and accu-
rate measurement (ADAM) automatic cell counter (NanoEnTek 
Inc., Seoul, South Korea).
rna Preparation
Total RNA was prepared in the whole cell lysates using TRIzol 
reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. A nanodrop spec-
trophotometer (Thermo Fisher Scientific, Waltham, MA, USA) 
were used to confirm the quality and quantity of extracted RNA.
Quantitative real-Time reverse 
Transcription Polymerase chain  
reaction (qrT-Pcr)
To examine mRNA expression, qRT-PCR was conducted. ReverTra 
Ace® qPCR RT Master Mix with gDNA Remover (Toyobo, Osaka, 
Japan) was used to synthesize cDNA with total RNA. The proce-
dures were according to the manufacturer’s instructions. qPCR 
BIO SyGreen Mix Hi-ROX (PCR BIOSYSTEMS, London, UK) 
was used to confirm the mRNA expression for genes of interest 
FigUre 1 | The experimental timeline of oxygen and glucose deprivation/reoxygenation (OGD/R) exposure and rMS stimulation. On day 0, the equal amount of 
Neuro-2a (N2a) cells were seeded in growth medium, which contains 10% fetal bovine serum (FBS) and 1% Penicillin–Streptomycin solution. At 70–80% confluency, 
the growth medium of N2a cells was changed into differentiation medium, which contains 20 µM of retinoic acid (RA) in Dulbecco’s Modified Eagle Medium (DMEM) 
for 4 days. After washing three times with PBS, the differentiation medium of N2a cells was changed into deoxygenated, glucose-free balanced salt solution (Gibco) 
and placed into a hypoxic chamber (O2 tension 1%) for 3 h. After this OGD injury, the cells were placed with medium and received on–off interval of 3 s stimulation for 
10 min. After the stimulation, the cells were incubated in a humidified atmosphere of 5% CO2 at 37°C. After 24 h, OGD/R+rMS cells were harvested for cell 
proliferation analysis, qRT-PCR, Western blot, ICC, and TUNEL assay. RA, retinoic acid; OGD/R, oxygen and glucose deprivation/reperfusion; rMS, repetitive magnetic 
stimulation; qRT-PCR, quantitive real-time reverse transcription polymerase chain reaction; ICC, immunocytochemistry; TUNEL, terminal dUTP nick end-labeling.
FigUre 2 | High-frequency repetitive magnetic stimulation (rMS) increases proliferation through the extracellular signal-regulated kinase (ERK) and AKT signaling 
pathway following oxygen and glucose deprivation/reoxygenation (OGD/R) injury. (a) Changed morphology of the cells was observed under microscope and 
photographed with a digital imaging system. (B) Bar graphs were shown for the proliferation rate of rMS stimulation following OGD/R injury. The white bars indicate 
OGD/R+sham group, the gray bars indicate OGD/R+low-frequency group, and the black bars indicate OGD/R+high-frequency group. Proliferation rate was 
represented as the mean ± SEM (OGD/R+sham group as control). ***p < 0.001 comparison with the OGD/R+sham group. ###p < 0.001 comparison with the OGD/
R+low-frequency group. (c) Western blot analysis with antibodies against p-ERK, t-ERK, p-AKT, t-AKT, and ACTIN. (D) Comparison of relative expression for 
p-ERK/ERK and p-AKT/AKT from the OGD/R+rMS-treated group versus the OGD/R+sham group. All results are expressed as means ± SEM. *p < 0.05, 
**p < 0.01, and ***p < 0.001 comparison with the OGD/R+sham group. ###p < 0.001 comparison with the OGD/R+low-frequency group.
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TaBle 1 | Primers used for quantitative real-time reverse transcription 
polymerase chain reaction (qRT-PCR).
gene symbol Forward primer (5′ → 3′) reverse primer (5′ → 3′)
GRIN1 CAG GAT CGT CAG  
GCA AGA CA
CCA AGC AAC TGA  
GGG TCC TT
CaMKIIα TGC TGC TCT TTC  
TCA CGC TG
TCA ATG GTG GTG  
TTG GTG CT
CaMKIIδ TGC ACC TGG TAG  
GGG ACG AT
GAA TAC AGG GTG  
GCT TGA TGG GT
BDNF GGG TCA CAG CGG  
CAG ATA AA
ATT GCG AGT TCC  
AGT GCC TT
Synaptophysin GTG CCA ACA AGA  
CGG AGA GT
CAC CCG AGG AGG  
AGT AGT CA
PSD-95 TCC CCA TTT TCT  
CCC ACA CAC
ACG GCG TGG GGA  
GTT ATG AT
GAPDH CAT CAC TGC CAC  
CCA GAA GAC TG
ATG CCA GTG AGC  
TTC CCG TTC AG
Grin 1, glutamate receptor ionotropic N-methyl-d-aspartate 1; CaMKIIα, calcium/
calmodulin-dependent protein kinase II alpha; CaMKIIδ, calcium/calmodulin-dependent 
protein kinase type II subunit delta; BDNF, brain-derived neurotrophic factor; 
PSD-95, postsynaptic density protein-95; GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase.
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in a StepOnePlus Real-Time PCR System (Applied Biosystems, 
Foster City, CA, USA). Data analysis was performed using the 
2−ΔΔCT method (32). Primers used for qRT-PCR are described in 
Table 1.
Western Blot
To confirm the protein expression, whole cell lysates were homog-
enized and dissolved with radioimmunoprecipitation assay buffer 
(Thermo Scientific) containing protease and phosphatase inhibi-
tors (Abcam, Cambridge, MA, USA). The BCA™ Protein Assay 
Kit (Thermo Scientific) was used to quantify the total protein. The 
samples were denatured and separated by 4–12% Bis-Tris gels in 
1× NuPage MES SDS Running Buffer (Invitrogen, Eugene, OR, 
USA). Proteins were transferred at 4°C onto a polyvinylidene 
difluoride membrane (Invitrogen) in NuPage Transfer Buffer 
(Invitrogen) with 20% (vol/vol) methanol. Membranes were 
blocked and then incubated overnight at 4°C with the follow-
ing antibodies: Anti-p-Erk1/2 (1:1,000 dilution, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), Anti-t-Erk1/2 (1:1,000 
dilution, Santa Cruz Biotechnology), Anti-p-AKT (1:1,000 dilu-
tion, Santa Cruz Biotechnology), Anti-t-AKT (1:1,000 dilution, 
Santa Cruz Biotechnology), Anti-BAX (1: 1,000 dilution, Santa 
Cruz Biotechnology), Anti-Bcl-2 (1:1,000 dilution, Santa Cruz 
Biotechnology), Anti-Cleaved-caspase-3 (1:1,000 dilution, Cell 
Signaling Technology, Danvers, MA, USA), Anti-Pro-caspase-3 
(1:1,000 dilution, Santa Cruz Biotechnology), Anti-N-methyl-d-
aspartate receptors1 (NMDAR1; 1: 1,000 dilution, Invitrogen), 
Anti-CaMKII (1:1,000 dilution, Abcam), Anti-CREB (1:1,000 
dilution, Santa Cruz Biotechnology), Anti-p-CREB (1:1,000 
dilution, Santa Cruz Biotechnology), Anti-BDNF (1:1,000 dilu-
tion, Abcam), and Anti-ACTIN (1:5,000 dilution, Santa Cruz 
Biotechnology). The next day, blots were washed three times with 
TBS plus Tween 20 and incubated at room temperature for 1 h 
with horseradish peroxidase-conjugated secondary antibodies 
(1:4,000 dilution, Santa Cruz). An enhanced chemiluminescence 
detection system (Amersham Pharmacia Biotech, Little Chalfont, 
UK) was used to visualize the protein.
immunocytochemistry (icc)
To confirm the expression of BDNF, Synaptophysin and post-
synaptic density protein-95 (PSD-95) in differentiated N2a cells 
were seeded into 0.2% gelatin (Sigma-aldrich, St. Louis, MO, 
USA) in PBS coated 4-well with OGD/R+rMS stimulation as 
described above. Cells were stained with Anti-BDNF (1:400 
dilution, Abcam), Anti-Synaptophysin (1:400 dilution, Abcam), 
and Anti-PSD-95 (1:400 dilution, Abcam) and incubated with 
Alexa Fluor® (1:400, Invitrogen) secondary antibody. Samples 
were mounted on glass slides with fluorescent mounting medium 
with 4′,6-diamidino-2-phenylindole (DAPI; Vectorshield, Vector 
Laboratories, Burlingame, CA, USA) for imaging using the Zeiss 
Axio Imager M2 (Carl Zeiss, Gottingen, Germany) fluorescence 
microscope.
Terminal dUTP nick end-labeling  
(TUnel) assay
For analysis of apoptosis, differentiated N2a cells were seeded into 
gelatin (Sigma-aldrich) coated 4-well. OGD/R and rMS stimula-
tion were performed as described above. Colorimetric TUNEL 
assay (Promega, Madison, WI, USA) was conducted according 
to the manufacturer’s protocol.
statistical analysis
All experiments were conducted at least three independent 
replications. The results were expressed as means ±  SEM. The 
Statistical Package for Social Sciences version 23.0 was used for 
statistical analysis. The one-way analysis of variance, followed 
by Bonferroni post hoc multi-comparison test was carried out to 
confirm the statistical results. Statistical differences were consid-
ered significant when p < 0.05.
resUlTs
high-Frequency rMs increases cell 
Proliferation through the activation of 
extracellular signal-regulated Kinase 
(erK) and aKT signaling Pathway after 
OgD/r injury
In the previous study (24), rMS affects cell proliferation in the 
neuroblastoma cells. Therefore, we evaluated cell proliferation 
with an ADAM, the automatic cell counting machine, after 
the stimulation with or without rMS following OGD/R injury. 
After 24 h following OGD/R+rMS stimulation, the proliferation 
rate of the OGD/R+low-frequency group (1.06 ± 0.16) was not 
significantly different compared to the OGD/R+sham group 
(Figure  2B). However, in the OGD/R+high-frequency group, 
proliferation rate was significantly increased compared to the 
OGD/R+sham group, and the proliferation rate and statistical 
value were as follows: 3.84 ± 0.64, p < 0.001 (Figure 2B). In the 
same manner, the proliferation rate of the OGD/R+high-frequency 
FigUre 3 | High-frequency repetitive magnetic stimulation (rMS) inhibits apoptosis expression following oxygen and glucose deprivation/reoxygenation (OGD/R) 
injury. (a) Western blot analysis with antibodies against Bcl-2-associated X protein (BAX), Bcl-2, Cleaved caspase-3, and Pro-caspase-3. (B) Comparison of relative 
expression apoptosis protein from the OGD/R+rMS treated group versus the OGD/R+sham group. All results are expressed as means ± SEM. *p < 0.05, 
**p < 0.01 and ***p < 0.001 comparison with the OGD/R+sham group. ##p < 0.01 and ###p < 0.001 comparison with the OGD/R+low-frequency group.  
(c) Detection of apoptosis with terminal dUTP nick end-labeling (TUNEL) assay in the rMS stimulation following OGD/R injury. Black arrow indicates apoptotic  
nuclei following OGD/R injury in differentiated Neuro-2a (N2a) cells.
5
Baek et al. rMS in I/R Injured Cell
Frontiers in Neurology | www.frontiersin.org February 2018 | Volume 9 | Article 50
high-Frequency rMs reduces apoptotic 
Process after OgD/r injury
It has been well demonstrated that neuronal apoptosis is one of 
the hallmarks of cerebral ischemia/reperfusion (I/R) injury (35). 
We constructed the OGD/R injury in differentiated neuronal 
cells to mimic the in vivo cerebral I/R conditions. Apoptotic pro-
cess was investigated using the protein expressions of apoptosis-
related proteins, such as Bcl-2-associated X protein (BAX), Bcl-2, 
Cleaved caspase-3, and Pro-caspase-3 (Figure  3A). As shown 
in Figures  3A,B, the OGD/R+high-frequency group showed 
significant decrease in the expression of pro-apoptotic proteins, 
such as BAX and Cleaved-caspase-3, while showing significant 
increase in the expression of anti-apoptotic proteins, as Bcl-2 
and Pro-caspase-3, compared to the OGD/R+sham group. The 
expression values were as follows: BAX (0.50 ± 0.08, p < 0.001), 
Bcl-2 (1.29 ± 0.04, p <  0.01), Cleaved-caspase-3 (0.28 ± 0.04, 
p < 0.001), and Pro-caspase-3 (1.36 ± 0.03, p < 0.001). In the 
OGD/R+low-frequency group compared to the OGD/R+sham 
group, the expression of pro-apoptotic proteins, such as BAX 
and Cleaved-caspase-3, was increased, while the expression of 
anti-apoptotic proteins, such as Bcl-2 and Pro-caspase-3, was 
decreased. The expression values were as follows: BAX (1.32 ± 
group was significantly increased compared to the OGD/R+low-
frequency group (p < 0.001) (Figure 2B).
Next, we investigated ERK and AKT pathway, which were 
known to play an important role in the development of synaptic 
plasticity and neurotrophic activity (33) as well as the regulation 
of growth and proliferation (24, 34), by western blot analysis 
(Figure  2C). The OGD/R+low-frequency group showed the 
decreased expression of p-ERK and p-AKT compared to the OGD/
R+sham group and the expression values were as follows: p-ERK/
ERK (0.88 ± 0.01, p < 0.05), p-AKT/AKT (0.90 ± 0.01, p < 0.01) 
(Figure  2D). By contrast, the OGD/R+high-frequency group 
showed the significantly activated p-ERK and p-AKT expression 
compared to the OGD/R+sham group, and the expression values 
were as follows: p-ERK/ERK (1.25 ± 0.02, p < 0.001) and p-AKT/
AKT (1.27 ± 0.04, p <  0.01) (Figure  2D). The OGD/R+high-
frequency group also showed the significant increased expression 
of p-ERK and p-AKT compared to the OGD/R+low-frequency 
group and the expression values were as follows: p-ERK/ERK 
(p < 0.001), p-AKT/AKT (p < 0.001) (Figure 2D).
Thus, we suggest that high frequency rMS increases cell 
proliferation via activation of ERK and AKT signaling pathway 
following OGD/R injury in differentiated neuronal cells.
FigUre 4 | High-frequency repetitive magnetic stimulation (rMS) activates Ca2+–calmodulin-dependent protein kinase II (CaMKII)–cAMP-response element binding 
protein (CREB) signaling pathway following oxygen and glucose deprivation/reoxygenation (OGD/R) injury. (a) GRIN1, CaMKIIα, and CaMKIIδ expressions were 
examined by quantitative real-time reverse transcription polymerase chain reaction. The relative expression of target genes was normalized by the OGD/R+sham 
group and was calculated using 2−ΔΔCt method. (B) Western blot analysis was performed using antibodies against N-methyl-d-aspartate receptors1(NMDAR1), 
CaMKII, p-CREB, and ACTIN (as control). (c) Comparison of relative expression apoptosis protein from the OGD/R+rMS-treated group versus the OGD/R+sham 
group. All results are expressed as means ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 comparison with the OGD/R+sham group. #p < 0.05, ##p < 0.01, and 
###p < 0.001 comparison with the OGD/R+low-frequency group.
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0.04, p <  0.001), Bcl-2 (0.95 ± 0.03), Cleaved-caspase-3 (1.15 
± 0.02, p < 0.05), and Pro-caspase-3 (1.02 ± 0.05). In the same 
manner, in the OGD/R+high-frequency group compared to the 
OGD/R+low-frequency group, the expression of pro-apoptotic 
proteins was statistically decreased, while the expression of 
anti-apoptotic proteins was statistically increased. The expres-
sion statistical values were as follows; BAX (p <  0.001), Bcl-2 
(p < 0.001), Cleaved-caspase-3 (p < 0.001), and Pro-caspase-3 
(p < 0.01).
To further investigate the underlying mechanism associated 
with apoptosis, we used TUNEL assay (Figure 3C). The number 
of TUNEL-positive nuclei was much observed in the OGD/
R+low-frequency group compared to the OGD/R+sham group 
or the OGD/R+high-frequency group. On the other hand, there 
were few TUNEL-positive nuclei in the OGD/R+high-frequency 
group compared to the OGD/R+sham group and the OGD/
R+low-frequency group.
These data suggest that high frequency rMS inhibits the pro-
gression of apoptosis following OGD/R injury in differentiated 
neuronal cells.
high-Frequency rMs increases  
ca2+–caMKii–creB signaling  
Pathway after OgD/r injury
In our previous study, we confirmed with transcriptome analysis 
that high frequency rMS can activate Ca2+–CaMKII–CREB 
signaling pathway, thus increasing the expression of p-CREB and 
BDNF via the activation of that signaling pathway in the neu-
ronal cells. We further evaluated Ca2+–CaMKII–CREB signaling 
pathway following OGD/R+rMS stimulation. By qRT-PCR, in the 
OGD/R+low-frequency group compared to the OGD/R+sham 
group, the expression of GRIN1, CaMKIIα, and CaMKIIδ was 
decreased (Figure 4A). The expression values as follows; GRIN1 
(0.71 ± 0.15), CaMKIIα (0.72 ± 0.05, p < 0.05), and CaMKIIδ 
(0.36 ± 0.05, p  <  0.001). In the OGD/R+high-frequency 
group, the expression of GRIN1, CaMKIIα, and CaMKIIδ was 
significantly increased compared to the OGD/R+sham group 
(Figure  4A). The expression values were as follows: GRIN1 
(1.85 ± 0.20, p <  0.01), CaMKIIα (1.27 ± 0.04, p <  0.05), and 
CaMKIIδ (1.28 ± 0.06, p <  0.01). Furthermore, in the OGD/
FigUre 5 | High-frequency repetitive magnetic stimulation increase brain-derived neurotrophic factor (BDNF) expression following oxygen and glucose deprivation/
reoxygenation (OGD/R) injury. (a) BDNF mRNA expression was examined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR).  
The relative expression of target gene was normalized by the OGD/R+sham group and was calculated using 2−ΔΔCt method. (B) Immunocytochemistry (ICC)  
was conducted to evaluate the level of BDNF. Scale bar: 50 µM, BDNF: Red, 4′,6-diamidino-2-phenylindole (DAPI): Blue.
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R+high-frequency group compared to the OGD/low-frequency 
group, the expression of GRIN1, CaMKIIα, and CaMKIIδ was 
significantly increased (Figure 4A). The statistical values were as 
follows: GRIN1 (p < 0.001), CaMKIIα (p < 0.001), and CaMKIIδ 
(p < 0.001).
Next, to further evaluate Ca2+–CaMKII–CREB signaling 
pathway, western blot was conducted (Figure 4B). In the OGD/
R+low-frequency group, the expression of N-methyl-d-aspartate 
receptors1 (NMDAR1), CaMKII, and p-CREB was decreased 
or no difference was shown compared to the OGD/R+sham 
group (Figure 4C). The expression values as follows: NMDAR1 
(0.87 ± 0.20), CaMKII (0.86 ± 0.02), and p-CREB (1.19 ± 0.02, 
p < 0.001). In the OGD/R+high-frequency group, the expression 
of NMDAR1, CaMKII, and p-CREB was increased compared 
to the OGD/R+sham group (Figure 4C). The expression values 
as follows: NMDAR1 (1.25 ± 0.03, p < 0.001), CaMKII (1.31 ± 
0.02, p <  0.001), and p-CREB (1.33 ± 0.01, p <  0.001). In the 
OGD/R+high-frequency group, the expression of NMDAR1, 
CaMKII, and p-CREB was increased compared to the OGD/
R+low-frequency group (Figure 4C). The statistical values were 
as follows: NMDAR1 (p <  0.001), CaMKII (p <  0.001), and 
p-CREB (p < 0.01).
Taken together, these data suggest that high frequency of 
rMS activates Ca2+–CaMKII–CREB signaling pathway following 
OGD/R injury in differentiated neuronal cells.
high-Frequency rMs increases BDnF 
expression after OgD/r injury
In the same manner, we examined the expression of BDNF fol-
lowing OGD/R+rMS stimulation. By qRT-PCR, we found that 
in the OGD/R+low-frequency group, the expression of BDNF 
was significantly decreased compared to the OGD/R+sham 
group, and the expression value was as a follow: BDNF (0.36 ± 
0.05, p <  0.001) (Figure  5A). In the OGD/R+high-frequency 
group, the expression of BDNF was significantly increased 
compared to the OGD/R+sham group and the expression value 
was as a follow: BDNF (1.33 ± 0.04, p <  0.001) (Figure  5A). 
Furthermore, in the OGD/R+high-frequency group compared 
to the OGD/R+low-frequency group, the expression of BDNF 
was significantly increased and the statistical value was as follow: 
BDNF (p < 0.001) (Figure 5A).
Then, we further evaluated BDNF expression with ICC 
analysis (Figure  5B). In the OGD/R+high-frequency group, 
the protein level of BDNF is significantly higher than the OGD/
R+low-frequency or sham group. BDNF expression was signifi-
cantly decreased, whereas high frequency rMS induces BDNF 
expression following OGD/R injury in differentiated neuronal 
cells.
We conclude that high frequency rMS increases BDNF expres-
sion via activation of Ca2+–CaMKII–CREB signaling pathway 
following OGD/R injury in differentiated neuronal cells.
FigUre 6 | High-frequency repetitive magnetic stimulation increases synaptic plasticity following oxygen and glucose deprivation/reoxygenation (OGD/R) injury.  
(a) Synaptophysin and postsynaptic density protein-95 (PSD-95) expressions were examined by qRT-PCR. The relative expression of target genes was normalized 
with respect to the OGD/R+sham group and was calculated using 2−ΔΔCt method. (B) Immunocytochemistry (ICC) was conducted to evaluate the level of 
synaptophysin and PSD-95. Scale bar: 50 µM, synaptophysin: Green, PSD-95: Red, 4′,6-diamidino-2-phenylindole (DAPI): Blue.
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high-Frequency rMs increases synaptic 
Plasticity after OgD/r injury
It is reported that the expression of p-CREB and BDNF is related 
to the regulation of synaptic plasticity (36, 37). We next assessed 
synaptic plasticity following OGD/R+rMS stimulation. By 
qRT-PCR, in the OGD/R+low-frequency group, the expression 
of synaptophysin, as a presynaptic marker, and PSD-95, as a 
postsynaptic marker, was significantly decreased compared to the 
OGD/R+sham group and the expression values were as follows: 
Synaptophysin (0.71 ± 0.07) and PSD-95 (0.41 ± 0.05, p < 0.01) 
(Figure 6A). In the OGD/R+high-frequency group, the expres-
sion of synaptophysin and PSD-95 was significantly increased 
compared to the OGD/R+sham group and the expression 
values were as follows: Synaptophysin (1.39 ± 0.12, p < 0.05) and 
PSD-95 (1.38 ± 0.04, p < 0.05) (Figure 6A). In the OGD/R+high-
frequency group compared to the OGD/R+low-frequency group, 
the expression of synaptophysin and PSD-95 was significantly 
increased and the statistical values were as follows: Synaptophysin 
(p < 0.001) and PSD-95 (p < 0.001) (Figure 6A).
Next, we performed ICC analysis to evaluate synaptic plastic-
ity (Figure 6B). In the OGD/R+low-frequency group, the protein 
level of synaptophysin and PSD-95 was not significantly different 
compared to the OGD/R+sham group. On the other hand, the 
protein level of synaptophysin and PSD-95 was significantly 
increased in the OGD/R+high-frequency group compared to the 
OGD/R+low-frequency or sham group.
These data indicated that high frequency rMS increases synap-
tic plasticity following OGD/R injury in differentiated neuronal 
cells.
DiscUssiOn
Several studies have been conducted to study the effect of rMS on 
neuronal recovery in the I/R injury model (3, 25, 38, 39). However, 
FigUre 7 | Schematic diagram of the therapeutic mechanisms of repetitive magnetic stimulation (rMS) following ischemia/reperfusion (I/R) injury. High-frequency 
rMS increases cell proliferation and mediates the protective effects against apoptosis induced by I/R injury. In addition to enhancing the Ca2+–calmodulin-dependent 
protein kinase II (CaMKII)–cAMP-response element binding protein (CREB) signaling pathway by high-frequency rMS, it also results in activation of brain-derived 
neurotrophic factor (BDNF) expression and synaptic plasticity in I/R injury.
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the neurobiological mechanism of rMS on the frequency dif-
ference in the I/R injury model has not been fully understood. 
Frequency-dependent stimulation with the same duration has 
been reported as the primary treatment regime of rMS (38–43). 
In this study, we developed an I/R injury model using neuronal 
cells and then applied different frequencies of rMS to it.
It was found that in the high frequency of rMS, cell prolifera-
tion was increased, and apoptotic process was decreased com-
pared to the sham or low-frequency rMS following I/R injury. 
We also verified that the activation of the Ca2+–CaMKII–CREB 
signaling pathway resulted in increased synaptic plasticity via 
increasing the expression of BDNF. These results are consistent 
with the previous studies using neuroblastoma cells, which were 
transformed neuron-liked cells (23, 24).
In this study, we constructed in vitro I/R injury model to verify 
accurate therapeutic mechanisms of rMS. When high-frequency 
rMS was applied to neuronal cells model with I/R injury, acti-
vation of the ERK and AKT signaling pathway promoted cell 
proliferation. These results are consistent with studies using 
neuroblastoma cells; the effects of rMS-induced cell proliferation 
were mediated by various growth factors, proliferation-, and 
survival-associated ERK and AKT (24). ERK and AKT signaling 
has been known to play an important role in the proliferation 
and maturation of neural progenitor cells (43, 44) as well as the 
regulation of migration of neuroblasts (45).
Next, we verified that high frequency of rMS inhibits the pro-
gression of apoptosis in differentiated neuronal cells model with 
I/R injury. This is in agreement with other in vivo studies. In a 
study of high-frequency rTMS using a subacute cerebral ischemic 
rat model, it was suggested that the anti-apoptotic mechanism is 
the main mechanism of rTMS treatment (39). Another study of 
the hippocampus area in an ischemic stroke rat model showed 
that high-frequency rTMS inhibited neuronal apoptosis in 
ischemic hemispheres (41). In this study, we verified in  vitro 
that high-frequency rMS inhibits the progression of apoptosis, 
indicating a protective role for the neuronal cells, which have 
been subjected to I/R injury.
In the brain, BDNF is known to improve neuronal survival, 
synaptogenesis, angiogenesis, and neurogenesis to regulate 
neuroplasticity (22, 42, 46, 47). It is also known that rMS affects 
the expression of BDNF in cultured hippocampal neurons (23). 
In particular, high frequency of rMS has been shown to increase 
BDNF expression (24, 25). Our previous study has also shown 
that the increased expression of BDNF by high-frequency rMS 
is due to the activation of the Ca2+–CaMKII–CREB signaling 
pathway.
In this study, using the same method as our previous study, we 
verified that BDNF expression was increased by the activation of 
the Ca2+–CaMKII–CREB signaling pathway with high-frequency 
stimulation in the I/R injury model as well. We also examined 
that synaptophysin, a presynaptic marker, and PSD-95, a post-
synaptic maker, were both found to increase in high-frequency 
rMS, thereby improving BDNF-mediated synaptic plasticity. It is 
thought that, when high-frequency rMS is applied, the various 
effects due to the increase expression of BDNF may act as a resto-
ring mechanism of the function after I/R injury.
In this study, low-frequency rMS to neuronal cells with I/R 
injury showed no direct positive effects in cell proliferation, 
anti-apoptosis, and synaptic plasticity. Previous studies in 
stroke patients suggested that low-frequency rTMS stimulates 
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the contralesional hemisphere rather than the lesion side, exert-
ing the positive indirect effect and lowering hyper-excitability 
(48). Therefore, additional follow-up studies will be needed to 
investigate the molecular mechanism of low frequency rTMS 
in stroke.
These findings call for further studies on varying degrees of 
cell regeneration after rMS application, by comparing groups 
applied with low- and high-frequency rMS after I/R injury and 
groups neither applied with rMS nor subjected to I/R injury. It 
is necessary to conduct basic studies to evaluate the functional 
aspect of cells regenerated by high frequency rMS. In addition, 
there is a study indicating that the expression of genes involved 
in cell recovery, such as cell repair and structural remodeling, 
increases after rTMS in a rat model of cerebral I/R injury (3). 
Based on this, further studies on cell recovery mechanism after 
rMS application may be helpful to understand the mechanism 
of rTMS.
As to the limitation of this study, our data are restricted to 
the effect of low- and high-frequency rMS over the same dura-
tion, which has been investigated in many previous studies. The 
different parameters such as the number of magnetic stimuli 
and duration cannot be disregarded (49–51). Therefore, further 
prospective studies to evaluate the effect of rMS based on the 
different durations for both low- and high-frequency rMS are 
needed.
In this study, we verified the neurobiological mechanism of 
rMS on I/R injury in neuronal cells, which depends on frequency. 
These results are valuable as a basic study for understanding the 
mechanism of rTMS treatment for stroke patients. This mecha-
nism may be useful in developing more robust and reliable rTMS 
treatment protocols.
cOnclUsiOn
Following I/R injury, neuronal cell death can be induced in an 
in vitro neuronal model (Figure 7). When high-frequency rMS is 
treated in the in vitro neuronal model of I/R injury, it can reduce 
neuronal cell death by increasing cell proliferation and anti-
apoptosis. Furthermore, it can also increase BDNF expression 
and synaptic plasticity by activating the Ca2+–CaMKII–CREB 
pathway. These results demonstrated the combined mechanism 
of high-frequency rMS in the in  vitro neuronal model, and its 
mechanism could also be applied to other neurological diseases.
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